Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis.

IF 4.9 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Annals of medicine Pub Date : 2023-12-01 DOI:10.1080/07853890.2023.2181983

Yan Wang, Qunqin Ni

{"title":"Prognostic and clinicopathological significance of Systemic Immune-Inflammation Index in cancer patients receiving immune checkpoint inhibitors: a meta-analysis.","authors":"Yan Wang, Qunqin Ni","doi":"10.1080/07853890.2023.2181983","DOIUrl":null,"url":null,"abstract":"Background: Among malignant neoplasm patients taking immune checkpoint inhibitors (ICIs), it remains unknown how the systemic immune-inflammation index (SII) affects their clinical prognosis. We therefore performed the present meta-analysis by collecting the most recent data, so that SII's prognostic value among ICI-receiving carcinoma patients could be fully clarified.Methods: For the prognostic significance evaluation of SII in ICI-receiving carcinoma patients, the combined hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.Results: The number of studies enrolled in the present meta-analysis totaled 17, where 1,990 patients were involved. Among the ICI-treated carcinoma patients, a high SII was linked significantly to inferior overall survival (OS) (HR = 2.62, 95% CI = 1.76-3.90), as well as progression-free survival (PFS) (HR = 2.09, 95% CI = 1.48-2.95) (p both <.001). Contrastively, SII was linked insignificantly to the age (OR = 1.08, 95% CI = 0.39-2.98, p = .881), gender (OR = 1.01, 95% CI = 0.59-1.73, p = .959), lymph node (LN) metastasis (OR = 1.41, 95% CI = 0.92-2.17, p = .117), or metastatic site quantity (OR = 1.49, 95% CI = 0.90-2.46, p = .119).Conclusion: There are prominent associations of elevated SII with the poor survival outcomes (both short- and long-terms) among the ICIreceiving carcinoma patients. SII has potential as a reliable and cheap prognostic biomarker in the clinic for carcinoma patients receiving ICIs.","PeriodicalId":8371,"journal":{"name":"Annals of medicine","volume":"55 1","pages":"808-819"},"PeriodicalIF":4.9000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07853890.2023.2181983","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Among malignant neoplasm patients taking immune checkpoint inhibitors (ICIs), it remains unknown how the systemic immune-inflammation index (SII) affects their clinical prognosis. We therefore performed the present meta-analysis by collecting the most recent data, so that SII's prognostic value among ICI-receiving carcinoma patients could be fully clarified.

Methods: For the prognostic significance evaluation of SII in ICI-receiving carcinoma patients, the combined hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.

Results: The number of studies enrolled in the present meta-analysis totaled 17, where 1,990 patients were involved. Among the ICI-treated carcinoma patients, a high SII was linked significantly to inferior overall survival (OS) (HR = 2.62, 95% CI = 1.76-3.90), as well as progression-free survival (PFS) (HR = 2.09, 95% CI = 1.48-2.95) (p both <.001). Contrastively, SII was linked insignificantly to the age (OR = 1.08, 95% CI = 0.39-2.98, p = .881), gender (OR = 1.01, 95% CI = 0.59-1.73, p = .959), lymph node (LN) metastasis (OR = 1.41, 95% CI = 0.92-2.17, p = .117), or metastatic site quantity (OR = 1.49, 95% CI = 0.90-2.46, p = .119).

Conclusion: There are prominent associations of elevated SII with the poor survival outcomes (both short- and long-terms) among the ICIreceiving carcinoma patients. SII has potential as a reliable and cheap prognostic biomarker in the clinic for carcinoma patients receiving ICIs.

查看原文本刊更多论文

接受免疫检查点抑制剂的癌症患者全身免疫炎症指数的预后和临床病理意义:一项荟萃分析。

背景：在服用免疫检查点抑制剂（ICIs）的恶性肿瘤患者中，系统免疫炎症指数（SII）如何影响其临床预后尚不清楚。因此，我们通过收集最新数据进行了本荟萃分析，以便能够充分阐明SII在接受ICI的癌症患者中的预后价值。方法：为了评估接受ICI治疗的癌症患者的SII的预后意义，估计综合危险比（HR）和95%置信区间（CI）。结果：本荟萃分析共纳入17项研究，涉及1990名患者。在ICI治疗的癌症患者中，高SII与低总生存率（OS）显著相关（HR = 2.62.95%CI = 1.76-3.90）以及无进展生存期（PFS）（HR = 2.09，95%CI = 1.48-2.95）（p均为p = .881），性别（或 = 1.01，95%CI = 0.59-1.73，p = .959）、淋巴结（LN）转移（OR = 1.41195%CI = 0.92-2.17，p = .117）或转移部位数量（or = 1.49，95%CI = 0.90-2.46，p = .119）。结论：在接受ICI治疗的癌症患者中，SII升高与较差的生存结果（短期和长期）存在显著关联。SII在接受ICIs的癌症患者的临床上具有作为可靠且廉价的预后生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of medicine 医学-医学：内科

CiteScore

4.90

自引率

0.00%

发文量

292

审稿时长

3 months

期刊介绍： Annals of Medicine is one of the world’s leading general medical review journals, boasting an impact factor of 5.435. It presents high-quality topical review articles, commissioned by the Editors and Editorial Committee, as well as original articles. The journal provides the current opinion on recent developments across the major medical specialties, with a particular focus on internal medicine. The peer-reviewed content of the journal keeps readers updated on the latest advances in the understanding of the pathogenesis of diseases, and in how molecular medicine and genetics can be applied in daily clinical practice.